JP2009534350A - 磁性ナノ粒子組成物およびその使用 - Google Patents
磁性ナノ粒子組成物およびその使用 Download PDFInfo
- Publication number
- JP2009534350A JP2009534350A JP2009505876A JP2009505876A JP2009534350A JP 2009534350 A JP2009534350 A JP 2009534350A JP 2009505876 A JP2009505876 A JP 2009505876A JP 2009505876 A JP2009505876 A JP 2009505876A JP 2009534350 A JP2009534350 A JP 2009534350A
- Authority
- JP
- Japan
- Prior art keywords
- core
- biocompatible
- nanoparticles
- composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1845—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carbohydrate (monosaccharides, discacharides)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Description
a)磁性物質、好ましくは強磁性物質を含むコアと;場合によって
b)コアを囲んでおり、外径が約100nm未満、好ましくは約50nm未満である生体適合性外殻と;場合によって
c)磁性物質または生体適合性層に結合することができる標識剤と
を含む、外部磁場と組み合わせた生体適合性ナノ粒子またはナノ粒子集合体の使用に関する。
a)磁性物質、好ましくは強磁性物質を含むコアと;場合によって
b)コアを囲んでおり、外殻の外径が約100nm未満、好ましくは約50nm未満である生体適合性外殻と;
c)磁性物質または生体適合性層に結合することができる標識剤と
を含む、外部磁場と組み合わせた生体適合性ナノ粒子またはナノ粒子集合体の使用に関する。
a)前述の群から選択された物質を用いて、例えば、酸化第一鉄および酸化第二鉄を用いて磁性コア、好ましくは強磁性コアを形成するステップと;好ましくは
b)コアの周りに生体適合性外殻、例えば、外径が約100nm未満、好ましくは50nm未満であるシリカ外殻を形成するステップとを含む。
a)磁性物質、好ましくは強磁性物質を含むコアと;場合によって
b)コアを囲んでおり、外殻の外径が約100nm未満、好ましくは約50nmまたは約50nm未満である生体適合性外殻とを含む、外部磁場と組み合わせた生体適合性ナノ粒子またはナノ粒子集合体の使用に関する。
a)本発明による医薬組成物および前述の医薬組成物を、前記医薬組成物に含まれるナノ粒子またはナノ粒子集合体に結合し、および/または内部に取り入れるために腫瘍細胞にとって十分な時間、腫瘍細胞と接触させるステップと;
b)曝露がナノ粒子に結合し、および/または内部に取り入れられている腫瘍細胞のアポトーシス、壊死または溶解を引き起こす、非振動または安定磁場に細胞を曝露させるステップと
を含む、インビトロ、エキソビボまたはインビボにおいて腫瘍細胞のアポトーシス、壊死または溶解を誘発または引き起こす方法に関する。
(実施例)
非標的ナノMAG組成物:3g非標的ナノMAG組成物/Lおよび6g非標的ナノMAG組成物/L
健常なオスのC57BL/6マウス6匹
3.2処理
投与経路:IV、ボーラス
注射容量:300μl/マウス/注射
処理用量:0.90および1.80mgの非標的ナノMAG組成物/マウス/注射
処理スケジュール:Q1D×1
0.90および1.80mg/非標的ナノMAG組成物/マウスの単回注射を含む忍容性試験を、以下の表2に記載のように達成した。
体重を週2回10日間記録した。
Claims (23)
- いかなる細胞ターゲティング手段も有していない、癌を予防または治療するための医薬組成物の製造のための、
a)強磁性物質を含むコアと;
b)前記コアを囲んでおり、外径が約100nm未満である生体適合性外殻と
を含む、外部の非振動磁場と組み合わせた生体適合性ナノ粒子またはナノ粒子集合体の使用。 - 前記強磁性物質が鉄、ニッケル、コバルト、ガドリニウム、サマリウム、ネオジム、ホウ素、アルミニウムおよびその任意の混合物から成る群から選択される、請求項1に記載の使用。
- 前記強磁性コア物質が酸化物、水酸化物または金属の形態である、請求項2に記載の使用。
- 前記強磁性物質がモノドメイン強磁性物質である、請求項3に記載の使用。
- 前記磁性コア物質が酸化第一鉄および酸化第二鉄から成る群から選択される、請求項4に記載の使用。
- 前記生体適合性外殻が、シリカ、金、アルミナ、砂糖、PEGおよびデキストランから成る群から選択された物質からできている、請求項1から5のいずれか一項に記載の使用。
- 前記外殻の外径が約10nmから約100nm未満の間である、請求項6に記載の使用。
- 前記外殻の外径が約10nmから約50nmの間である、請求項7に記載の使用。
- 前記ナノ粒子が、磁性物質に結合した標識剤をさらに含む、請求項1から8のいずれか一項に記載の使用。
- 前記ナノ粒子またはナノ粒子集合体が本質的に球状または円形形状を有する、請求項1から9のいずれか一項に記載の使用。
- いかなる細胞ターゲティング手段も有していない、癌細胞、癌組織または癌器官の治療および検出または可視化を目的とするモニタリング用組成物の製造のための、
a)強磁性物質を含むコアと;
b)前記コアを囲んでおり、外径が約100nm未満である生体適合性外殻と;
c)標識剤と
を含む、外部磁場と組み合わせた生体適合性ナノ粒子またはナノ粒子集合体の使用。 - 前記磁場が、治療活性を生じるために任意の磁場源を使用することによって印加される、請求項1から11のいずれか一項に記載の使用。
- 前記磁場源が均一および一方向性の磁場源である、請求項12に記載の使用。
- 前記磁場源が任意の電磁石および磁気共鳴映像法(MRI)装置から選択される、請求項12または13に記載の使用。
- スキャナーまたはX線撮影法または超音波が可視化の目的に使用される、請求項11に記載の使用。
- a)強磁性物質を含むコアと;b)前記コアを囲んでおり、外径が、生体適合性担体と関連して、約100nm未満である生体適合性外殻とを含む生体適合性ナノ粒子またはナノ粒子集合体を含む、いかなる細胞ターゲティング作用物質も有していない医薬組成物。
- 前記強磁性コア物質が酸化第一鉄および酸化第二鉄から成る群から選択される、請求項16に記載の組成物。
- 前記外殻の外径が約10nmから約50nmの間である、請求項16または17に記載の組成物。
- 前記ナノ粒子またはナノ粒子集合体が本質的に球状または円形形状を有する、請求項16から18のいずれか一項に記載の組成物。
- a)強磁性物質を含むコアと;b)前記コアを囲んでおり、外径が、生体適合性担体と関連して、約100nm未満、好ましくは50nm未満である生体適合性外殻と、c)標識剤とを含む生体適合性ナノ粒子またはナノ粒子集合体を含む、いかなる細胞ターゲティング作用物質も有していない診断用組成物。
- 前記強磁性コア物質が酸化第一鉄および酸化第二鉄から成る群から選択される、請求項20に記載の化合物。
- 前記外殻の外径が約10nmから約50nmの間である、請求項20または21に記載の組成物。
- 前記ナノ粒子またはナノ粒子集合体が本質的に球状または円形形状を有する、請求項20から22のいずれか一項に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74509606P | 2006-04-19 | 2006-04-19 | |
EP06290638.3 | 2006-04-19 | ||
EP06290638A EP1852107A1 (en) | 2006-04-19 | 2006-04-19 | Magnetic nanoparticles compositions and uses thereof |
US60/745,096 | 2006-04-19 | ||
PCT/EP2007/053761 WO2007118884A1 (en) | 2006-04-19 | 2007-04-18 | Magnetic nanoparticles compositions and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009534350A true JP2009534350A (ja) | 2009-09-24 |
JP5266548B2 JP5266548B2 (ja) | 2013-08-21 |
Family
ID=37103135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009505876A Expired - Fee Related JP5266548B2 (ja) | 2006-04-19 | 2007-04-18 | 磁性ナノ粒子組成物およびその使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100040555A1 (ja) |
EP (2) | EP1852107A1 (ja) |
JP (1) | JP5266548B2 (ja) |
AT (1) | ATE530168T1 (ja) |
CA (1) | CA2649207C (ja) |
EA (1) | EA016541B1 (ja) |
ES (1) | ES2375510T3 (ja) |
WO (1) | WO2007118884A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012012377A (ja) * | 2009-10-05 | 2012-01-19 | Canon Inc | 光音響イメージング用造影剤及び前記光音響イメージング用造影剤を用いた光音響イメージング方法 |
JP2013540745A (ja) * | 2010-09-20 | 2013-11-07 | ナノフタルミックス エルエルシー | 超常磁性特性を有するナノ粒子からなる医療用材料及びその外科手術における使用 |
JP2016532674A (ja) * | 2013-07-12 | 2016-10-20 | ブロッセル,レミー | 拘束場を生成するシステムおよびそれを実装する医療装置 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2481570C2 (ru) | 2007-01-24 | 2013-05-10 | Конинклейке Филипс Электроникс Н.В. | Способ воздействия на магнитные частицы и/или детектирования магнитных частиц в зоне действия, магнитные частицы и применение магнитных частиц |
EP2152320A2 (en) | 2007-04-30 | 2010-02-17 | Intezyne Technologies Incorporated | Encapsulated contrast agents |
FR2923730B1 (fr) * | 2007-11-19 | 2009-12-25 | Inst Nat Sciences Appliq | Procede de fabrication de nanoparticules metalliques enrobees de silice. |
WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
ITFI20070285A1 (it) * | 2007-12-19 | 2009-06-20 | Colorobbia Italiana Spa | Nanosfere con superficie esterna in metalli nobili. |
US8563043B2 (en) | 2009-03-23 | 2013-10-22 | The General Hospital Corporation | Innately multimodal nanoparticles |
CA2857260C (en) | 2011-12-16 | 2019-10-15 | Nanobiotix | Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof |
WO2014130488A1 (en) * | 2013-02-19 | 2014-08-28 | University Of Massachusetts | Functionalized nanoparticles for medical treatments |
US20160010080A1 (en) * | 2014-07-09 | 2016-01-14 | Magqu Co., Ltd. | A method for preparing silica-coated magnetic bead |
US20170258718A1 (en) | 2014-11-25 | 2017-09-14 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
FI3229776T3 (fi) | 2014-11-25 | 2023-08-15 | Curadigm Sas | Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt |
NZ738527A (en) | 2015-05-28 | 2022-07-01 | Nanobiotix | Nanoparticles for use as a therapeutic vaccine |
WO2017147266A1 (en) * | 2016-02-23 | 2017-08-31 | The University Of Florida Research Foundation, Inc. | Magnetic nanoparticles and methods of making magnetic nanoparticles |
WO2018150362A1 (en) * | 2017-02-16 | 2018-08-23 | Vegrandis Therapeutics Pvt. Ltd. | Magnetic nanoparticle formulations for targeted delivery of drugs to lungs for treatment of pulmonary diseases |
WO2021010586A1 (ko) * | 2019-07-15 | 2021-01-21 | (주)심플스틱 | 항노화를 위한 피부 리프팅용 화장료 조성물 및 이를 이용한 피부미용 방법 |
WO2023214201A1 (en) | 2022-05-03 | 2023-11-09 | Abdula Kurkayev | Method of obtaining stable suspensions of heterocrystals of titanium dioxide and particles of silicon dioxide and stable suspensions obtained by this method for initiation of active form of oxygen in body at use in medical forms |
CN117355311A (zh) | 2022-05-05 | 2024-01-05 | 阿卜杜拉·库尔卡耶夫 | 用于恢复生物体生理过程和细胞的药物组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001523693A (ja) * | 1997-11-20 | 2001-11-27 | ディヴィッド プラット | 腫瘍の治療及び/又は映像化剤 |
US20040208825A1 (en) * | 2003-04-15 | 2004-10-21 | Carpenter Everett E. | Fluorescent-magnetic nanoparticles with core-shell structure |
WO2005015213A1 (en) * | 2003-08-08 | 2005-02-17 | Tsinghua University | Fluorescent magnetic nanoparticles and process of preparation |
WO2005013897A2 (en) * | 2003-07-10 | 2005-02-17 | Triton Biosystems, Inc. | Magnetic nanoparticle compositions, and methods related thereto |
WO2005046733A1 (en) * | 2003-11-17 | 2005-05-26 | Philips Intellectual Property & Standards Gmbh | Contrast agent for medical imaging techniques and usage thereof |
WO2005120590A1 (fr) * | 2004-05-10 | 2005-12-22 | Nanobiotix | Particules activables, preparation et utilisations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4770183A (en) * | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
WO1994002068A1 (en) * | 1992-07-21 | 1994-02-03 | The General Hospital Corporation | System of drug delivery to the lymphatic tissues |
TW334434B (en) | 1995-05-16 | 1998-06-21 | Kanebo Ltd | Novel quinazoline compound and anti-tumor agent |
DE19726282A1 (de) * | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
US6514481B1 (en) | 1999-11-22 | 2003-02-04 | The Research Foundation Of State University Of New York | Magnetic nanoparticles for selective therapy |
DE10154016B4 (de) * | 2001-10-26 | 2004-02-12 | Berlin Heart Ag | Magnetflüssigkeit und Verfahren zur ihrer Herstellung |
US20030125283A1 (en) * | 2002-09-16 | 2003-07-03 | Gatenby Robert A. | Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents |
US20050260137A1 (en) * | 2004-05-18 | 2005-11-24 | General Electric Company | Contrast agents for magnetic resonance imaging |
GB2415374A (en) * | 2004-06-25 | 2005-12-28 | Leuven K U Res & Dev | Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles |
-
2006
- 2006-04-19 EP EP06290638A patent/EP1852107A1/en not_active Withdrawn
-
2007
- 2007-04-18 WO PCT/EP2007/053761 patent/WO2007118884A1/en active Application Filing
- 2007-04-18 CA CA2649207A patent/CA2649207C/en not_active Expired - Fee Related
- 2007-04-18 EA EA200870447A patent/EA016541B1/ru not_active IP Right Cessation
- 2007-04-18 JP JP2009505876A patent/JP5266548B2/ja not_active Expired - Fee Related
- 2007-04-18 EP EP07728223A patent/EP2010152B1/en not_active Not-in-force
- 2007-04-18 ES ES07728223T patent/ES2375510T3/es active Active
- 2007-04-18 US US12/296,732 patent/US20100040555A1/en not_active Abandoned
- 2007-04-18 AT AT07728223T patent/ATE530168T1/de not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001523693A (ja) * | 1997-11-20 | 2001-11-27 | ディヴィッド プラット | 腫瘍の治療及び/又は映像化剤 |
US20040208825A1 (en) * | 2003-04-15 | 2004-10-21 | Carpenter Everett E. | Fluorescent-magnetic nanoparticles with core-shell structure |
WO2005013897A2 (en) * | 2003-07-10 | 2005-02-17 | Triton Biosystems, Inc. | Magnetic nanoparticle compositions, and methods related thereto |
WO2005015213A1 (en) * | 2003-08-08 | 2005-02-17 | Tsinghua University | Fluorescent magnetic nanoparticles and process of preparation |
WO2005046733A1 (en) * | 2003-11-17 | 2005-05-26 | Philips Intellectual Property & Standards Gmbh | Contrast agent for medical imaging techniques and usage thereof |
WO2005120590A1 (fr) * | 2004-05-10 | 2005-12-22 | Nanobiotix | Particules activables, preparation et utilisations |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012012377A (ja) * | 2009-10-05 | 2012-01-19 | Canon Inc | 光音響イメージング用造影剤及び前記光音響イメージング用造影剤を用いた光音響イメージング方法 |
JP2013540745A (ja) * | 2010-09-20 | 2013-11-07 | ナノフタルミックス エルエルシー | 超常磁性特性を有するナノ粒子からなる医療用材料及びその外科手術における使用 |
US9427354B2 (en) | 2010-09-20 | 2016-08-30 | Nanophthalmics, Llc | Material for medical use comprising nanoparticles with superparamagnetic properties and its utilization in surgery |
JP2016532674A (ja) * | 2013-07-12 | 2016-10-20 | ブロッセル,レミー | 拘束場を生成するシステムおよびそれを実装する医療装置 |
US10449160B2 (en) | 2013-07-12 | 2019-10-22 | Cell Constraint & Cancer (Cc&C) | System generating a constraint field, and medical device implementing the same |
Also Published As
Publication number | Publication date |
---|---|
CA2649207A1 (en) | 2007-10-25 |
EP2010152A1 (en) | 2009-01-07 |
EA200870447A1 (ru) | 2009-10-30 |
EP1852107A1 (en) | 2007-11-07 |
ES2375510T3 (es) | 2012-03-01 |
WO2007118884A1 (en) | 2007-10-25 |
JP5266548B2 (ja) | 2013-08-21 |
US20100040555A1 (en) | 2010-02-18 |
ATE530168T1 (de) | 2011-11-15 |
EA016541B1 (ru) | 2012-05-30 |
EP2010152B1 (en) | 2011-10-26 |
CA2649207C (en) | 2014-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5266548B2 (ja) | 磁性ナノ粒子組成物およびその使用 | |
Bayda et al. | Inorganic nanoparticles for cancer therapy: a transition from lab to clinic | |
Vallabani et al. | Magnetic nanoparticles: current trends and future aspects in diagnostics and nanomedicine | |
Kolosnjaj-Tabi et al. | Heat-generating iron oxide nanocubes: Subtle “destructurators” of the tumoral microenvironment | |
Weissig et al. | Nanopharmaceuticals (part 2): products in the pipeline | |
Hayashi et al. | High-frequency, magnetic-field-responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect | |
Laurent et al. | Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer | |
Pernal et al. | Hydroxyapatite as a vehicle for the selective effect of superparamagnetic iron oxide nanoparticles against human glioblastoma cells | |
Lu et al. | Enhanced anticancer effect of ROS-boosted photothermal therapy by using fucoidan-coated polypyrrole nanoparticles | |
Mahmood et al. | Engineered nanostructural materials for application in cancer biology and medicine | |
JP2009536151A (ja) | ナノ粒子 | |
Tang et al. | Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives | |
Li et al. | Ultralong tumor retention of theranostic nanoparticles with short peptide-enabled active tumor homing | |
Shin et al. | One-dimensional nanomaterials for cancer therapy and diagnosis | |
Zhao et al. | Thermochemotherapy mediated by novel solar-planet structured magnetic nanocomposites for glioma treatment | |
Panda et al. | Smart nanomaterials as the foundation of a combination approach for efficient cancer theranostics | |
Gulati et al. | Biocompatible chitosan-coated gold nanoparticles: novel, efficient, and promising Nanosystems for Cancer treatment | |
Zheng et al. | Recent advances in superparamagnetic iron oxide based nanoprobes as multifunctional theranostic agents for breast cancer imaging and therapy | |
Shabani et al. | The brilliance of nanoscience over cancer therapy: Novel promising nanotechnology-based methods for eradicating glioblastoma | |
Monteserín et al. | Recent advances in the development of magnetic nanoparticles for biomedical applications | |
KR20190094699A (ko) | 빌리루빈 유도체 기반의 진단 및 치료용 초음파 조영제 | |
Vukadinović et al. | 90Y-CA/SPIONs for dual magnetic hyperthermia-radionuclide nanobrachytherapy of solid tumours | |
Qi et al. | Research progress on carbon materials in tumor photothermal therapy | |
Abueva | Photo-triggered theranostic nanoparticles in cancer therapy | |
RU2622025C2 (ru) | Агломерирование магнитных покрытых алкоксисиланом наночастиц |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121106 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121114 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130222 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130222 |
|
TRDD | Decision of grant or rejection written | ||
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130318 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130319 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130416 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |